Radar · Life Sciences in Waltham
Best Life Sciences Companies in Waltham, United States
The 126 best Life Sciences companies in Waltham, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Adagio.
By Riya SenguptaFinancials
126companies tracked
$7.2Bdisclosed funding
1unicorns
87have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × WALTHAM
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
437kcombined LinkedIn audience
34%of audience held by top 3
6companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Waltham
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Adagio Developer of antibodies for the treatment of SARS-CoV-2 | $466M | 62 mo ago | 68 | Laura Walker Co-Founder & CSO | — | — | 9 job openings |
| 2 | Kailera Developer of therapies for treating obesity and related conditions 60Funding top 12%Growth top 20%News top 22%Moat top 31% All 8 signals ▾Fundingtop 12% Growthtop 20% Newstop 22% Moattop 31% Techtop 40% Talentbottom 41% Globalbottom 38% Marketbottom 36% Funding: Raised $400M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 60/100 | $400M | 8 mo ago | — | Ron Renaud Founder & CEO | DrupalApple iCloud MailPHP+27 | — | 1 internship |
| 3 | Upstream Bio Developer of therapeutics for allergic and inflammatory diseases | $400M | 36 mo ago | 33 | Oren Becker Founder | DrupalPHPAmazon Web Services+14 | — | 4 job openings |
| 4 | Repligen Provider of services for manufacturing biological drugs | $389M | 106 mo ago | 841 841 → 1,460 (+74%) · sector median +33% | Paul Schimmel Co-Founder | Cart FunctionalityShopifyBootstrap+32 | 579 patents Bioprocess analytics and purification: spectroscopic monitoring, chromatography media, affinity ligands. | 1 launch |
| 5 | Minerva Neurosciences Innovating central nervous system disorder treatments with clinical expertise and patient focus 50Patents top 22%Funding top 26%Innovation top 27%Fin. health bottom 48% All 9 signals ▾Patentstop 22% Fundingtop 26% Innovationtop 27% Fin. healthbottom 48% Moatbottom 48% Globalbottom 44% Techbottom 40% Marketbottom 38% Newsbottom 38% Patents: 216 patents matched (strict assignee match) · 111 filings since 2022 vs 89 in 2017-21 Funding: Raised $247M across 4 rounds · 4 rounds over 11 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $247M | 8 mo ago | 10 | — | WordPressMySQLPHP+14 | 216 patents Novel CNS drug molecules and gastro-resistant oral formulations for psychiatric and metabolic disorders | — |
| 6 | Xilio Therapeutics Developer of immunotherapies for the treatment of cancer 67Funding top 25%Growth top 27%Moat top 28%Fin. health top 41% All 9 signals ▾Fundingtop 25% Growthtop 27% Moattop 28% Fin. healthtop 41% Markettop 43% Techtop 45% Talentbottom 49% Newsbottom 46% Globalbottom 39% Funding: Raised $233M across 5 rounds · 5 rounds over 10 yrs (0.5/yr) Growth: Headcount 30 → 72 (+140%) across vintages · Revenue +590% YoY rank vs industry peers · Fliar Intelligence Index 67/100 | $233M | 16 mo ago | 72 72 → 96 (+33%) · sector median +33% | Rene Russo CEO | WordPressDrupalMySQL+31 | — | — |
| 7 | Scipher Medicine Provider of precision medicine based on liquid biopsy test | $231M | 25 mo ago | 126 | Joseph Loscalzo Co-Founder | — | 29 patents AI-driven personalized therapy monitoring and response prediction for anti‑TNF treatments | — |
| 8 | Avedro Developer of corneal collagen cross-linking technology | $211M | 97 mo ago | 113 | — | — | 374 patents Corneal cross‑linking devices and diagnostics for ophthalmic treatment and eye‑tracking. | — |
| 9 | Triveni Bio Developer of functional antibodies for the treatment of immunological and inflammatory disorders | $207M | 20 mo ago | — | Vishal Patel CEO | — | — | — |
| 10 | BostonGene 🦄 Developer of cloud-based information and analytics platform to treat cancer | $200M | 50 mo ago | 46 | Andrew Feinberg President & CEO | StatamicSentryPHP+19 | 229 patents Cancer immunology profiling and tumor microenvironment analysis using multiplex imaging and cytometry | 1 award |
| 11 | Syndax Developer of targeted therapies for the treatment of cancer | $195M | 76 mo ago | 107 | — | Apple iCloud MailNode.jsTypeScript+14 | — | 1 internship · 1 partnership · 1 award |
| 12 | Skyhawk Therapeutics Developer of RNA-modifying drug candidates for the treatment of multiple disorders | $181M | 57 mo ago | 86 | — | WixSentryBootstrap+14 | 229 patents RNA splicing modulators for treating neurodegenerative diseases | 1 launch |
| 13 | Deciphera Developer of type 2 kinase inhibitors for treating cancer | $173M | 108 mo ago | 394 394 → 539 (+37%) · sector median +33% | — | DrupalApple iCloud MailMariaDB+11 | — | — |
| 14 | Tesaro Global biopharma innovating medicines in respiratory, immunology, oncology, HIV, and infectious diseases | $161M | 96 mo ago | 502 | — | — | 381 patents PARP inhibitor oncology and immune checkpoint antibody therapies for various cancers | — |
| 15 | Apogee Therapeutics Developer of therapeutics for immunological and inflammatory disorders | $149M | 42 mo ago | 91 | Nimish Shah Co-Founder | DrupalApple iCloud MailMicrosoft 365+24 | — | — |
| 16 | Morphic Therapeutic Developer of small molecule integrin inhibitors for immunological, fibrotic, neoplastic and vascular diseases | $132M | 39 mo ago | 121 | Praveen Tipirneni CEO | — | 233 patents Therapeutic integrin inhibition and antibody development for disease modulation | — |
| 17 | ANDE Rapid DNA technology for human identification, energy, and biosurveillance solutions | $131M | 74 mo ago | 55 | Richard Selden Founder & Chairman | Cart FunctionalitySquarespace CommerceSquarespace+17 | 97 patents Patents concentrated in transport & manufacturing processes | — |
| 18 | OncXerna Developer of therapeutics to treat cancer | $126M | 51 mo ago | 18 | — | — | — | — |
| 19 | ImmunoGen Developer of antibody drug conjugates for the treatment of cancer | $126M | 120 mo ago | 106 | Mark Enyedy CEO & President | — | 2,714 patents Antibody-drug conjugates targeting folate receptor, EPCAM, CD123 for oncology | — |
| 20 | Entasis Therapeutics Developer of a portfolio of cures for serious drug-resistant bacterial infections | $122M | 69 mo ago | 40 | — | — | — | — |
| 21 | Histogenics Developer of restorative cell therapies for orthopedic diseases | $116M | 117 mo ago | 84 | — | — | 121 patents Adhesive scaffolds and porous matrices for articular cartilage regeneration. | — |
| 22 | Kala Pharmaceuticals Developer of ophthalmic treatments based on its mucosal penetrating product platform 45Funding top 22%Product top 24%Talent top 33%News top 34% All 12 signals ▾Fundingtop 22% Producttop 24% Talenttop 33% Newstop 34% Moattop 35% Patentstop 37% Innovationtop 41% Techbottom 49% Marketbottom 42% Growthbottom 42% Globalbottom 40% Fin. healthbottom 36% Funding: Raised $115M across 14 rounds · 14 rounds over 17 yrs (0.8/yr) Product: 2 distinct product lines · Company stage: Public rank vs industry peers · Fliar Intelligence Index 45/100 | $115M | 3 mo ago | 34 34 → 80 (+135%) · sector median +33% | Justin Hanes Co-Founder | DrupalApple iCloud MailPHP+20 | 267 patents Mucosal and ocular drug delivery via nanoparticle and polymer-based pharmaceutical formulations | — |
| 23 | Arrakis Therapeutics Provider of tools for the analysis of RNA structures | $113M | 86 mo ago | 89 89 → 51 (-43%) · sector median +33% | Russell Petter Co-Founder & CSO | WordPressMySQLPHP+18 | — | — |
| 24 | Axial Therapeutics Developer of small molecule therapeutics for central nervous system disorder | $110M | 16 mo ago | 12 12 → 12 (+0%) · sector median +33% | A Campbell CEO | — | — | — |
| 25 | TRIANA Biomedicines Developer of precision medicine for the treatment of cancer 45Funding top 24%Moat top 28%Talent top 38%Patents top 41% All 9 signals ▾Fundingtop 24% Moattop 28% Talenttop 38% Patentstop 41% Newstop 43% Innovationtop 47% Techbottom 46% Marketbottom 42% Globalbottom 31% Funding: Raised $110M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 21 patents rank vs industry peers · Fliar Intelligence Index 45/100 | $110M | 6 mo ago | 38 | Jesse Chen Co-Founder & Chief Technology Officer | Cart FunctionalitySquarespace CommerceSquarespace+19 | 21 patents Patents concentrated in chemistry & materials | 2 internships |
| 26 | Nocion Therapeutics Developer of therapeutics for the treatment of multiple diseases 42Funding top 23%Talent top 28%Moat top 39%Global bottom 39% All 6 signals ▾Fundingtop 23% Talenttop 28% Moattop 39% Globalbottom 39% Marketbottom 34% Newsbottom 18% Funding: Raised $104M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $104M | 6 mo ago | 15 15 → 19 (+27%) · sector median +33% | Clifford Woolf Co-Founder | — | — | — |
| 27 | Mythic Therapeutics Developer of antibody-drug conjugates for the treatment of cancer | $103M | 54 mo ago | 12 12 → 10 (-17%) · sector median +33% | Brian Fiske Co-Founder | WordPressMySQLPHP+29 | — | — |
| 28 | Dianthus Therapeutics Developer of antibody therapeutics to treat rare autoimmune diseases | $100M | 50 mo ago | 27 | Marino Garcia President & Chief Executive Officer | WordPressApple iCloud MailMySQL+21 | — | 1 job opening · 1 launch |
| 29 | Arsanis Developer of monoclonal antibodies to treat infectious diseases | $91M | 102 mo ago | 73 | — | — | — | — |
| 30 | Corvidia Therapeutics Southeast Asia's leading eCommerce platform accelerating progress through commerce and technology | $86M | 97 mo ago | 9 | — | — | — | — |
| 31 | Chrono Therapeutics A transdermal nicotine replacement therapy for smoking cessation. | $82M | 116 mo ago | 31 | — | — | — | — |
| 32 | SpectraWAVE Provider of diagnostic photonic imaging | $80M | 21 mo ago | 36 36 → 29 (-19%) · sector median +33% | Gregg Stone Co-Founder | WordPress Block EditorBeaver BuilderWordPress+23 | 35 patents Intravascular and anatomical imaging systems for plaque assessment and optical fiber radiation control | — |
| 33 | Logical Therapeutics Develops drugs that treat diseases associated with inflammation | $79M | 193 mo ago | — | Mitchell Fink CEO | — | — | — |
| 34 | Sojournix Developer of drugs for hot flashes due to menopause | $78M | 91 mo ago | 7 | — | — | 16 patents Polymorphic and deuterated isoquinolinone forms for pharmaceutical applications | — |
| 35 | OvaScience Developer of new fertility treatments for women | $77M | 158 mo ago | 19 | Chris Kroeger CEO | — | 43 patents Reproductive biotech: anti‑VASA antibodies and in‑vitro oocyte generation from ovarian culture | — |
| 36 | Avilar Provider of drug discovery platform and protein degradation technology | $75M | 66 mo ago | 12 12 → 25 (+108%) · sector median +33% | Jesse Chen Co-Founder and Advisor | — | — | — |
| 37 | Pretzel Developer of therapeutics to treat rare genetic disorders and mitochondrial dysfunction | $72M | 45 mo ago | 5 | Paul Thurk Co-Founder | WordPressApple iCloud MailMySQL+16 | — | 2 job openings |
| 38 | Pyramid Bio Developer of small molecules for the treatment of dermatology and cancer | $71M | 56 mo ago | 3 | — | — | — | — |
| 39 | Arsenal Medical Developer of polymer-based foams and fibers 45Funding top 20%Talent top 23%Product top 26%Moat top 26% All 10 signals ▾Fundingtop 20% Talenttop 23% Producttop 26% Moattop 26% Patentstop 27% Innovationtop 35% Techbottom 39% Globalbottom 38% Marketbottom 26% Newsbottom 22% Funding: Raised $69.9M across 21 rounds · 21 rounds over 21 yrs (1.0/yr) Talent: 5 named leaders on record · 5 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $70M | 10 mo ago | 16 16 → 29 (+81%) · sector median +33% | Eric Stern Co-Founder & CTO | WordPressMySQLPHP+15 | 190 patents Hemostatic and embolic biomaterial devices for bleeding control and vascular occlusion. | — |
| 40 | Naveris Provider of blood tests for early cancer detection | $69M | 24 mo ago | 53 | Piyush Gupta Founder & CEO | WordPressApple iCloud MailMySQL+21 | — | — |
| 41 | SHYFT Analytics Data Management and analytic solutions for life sciences | $62M | 110 mo ago | 151 | — | — | — | — |
| 42 | EyeGate Affordable medications and healthcare products provider with a focus on customer well-being | $44M | 58 mo ago | 12 | — | Cart FunctionalityWordPressMySQL+10 | — | — |
| 43 | Amagma Developer of antibody therapies for treating inflammatory diseases | $29M | 41 mo ago | 10 | Leonard Zon Co-Founder | — | — | 1 expansion · 1 award |
| 44 | Thermedical Developer of thermal ablation therapy for ventricular tachycardia | $28M | 33 mo ago | — | Michael Curley Founder | — | 128 patents Catheter-based cardiac ablation devices: fluid delivery, temperature monitoring, instrument deployment | — |
| 45 | AVAVA Platform offering intradermal energy solutions for skin treatments | $25M | 4 mo ago | 1 | Irina Erenburg CEO | WordPressApple iCloud MailMicrosoft 365+30 | 158 patents Medical laser treatment devices with real-time feedback and motion‑tracking systems | 1 job opening |
| 46 | SeQure Dx Developer of personalized diagnostics for gene-editing therapies | $22M | 30 mo ago | 29 | — | — | 6 patents Targeted DNA amplification and enrichment for detecting genomic rearrangements in diagnostics | — |
| 47 | Minerva Biotechnologies Developer of cell therapy and antibodies to treat cancer | $19M | 31 mo ago | 24 | — | Cart FunctionalityPHPGSAP+8 | 480 patents Therapeutic/diagnostic MUC1 antibodies, NME7 bacterial enzymes, stem‑cell dopaminergic neuron production | — |
| 48 | Function Promoting Therapies Developer of diagnostic tools and sustained testosterone delivery systems | $9M | 14 mo ago | — | Satish Vankayalapati Founder | — | 13 patents Diagnostic and therapeutic systems for androgen and sex hormone disorder detection and treatment | — |
| 49 | Ypsilon Tx Developer of therapeutics for cancer treatment | $3M | 16 mo ago | — | Dongxing Zha Co-Founder and CEO | — | — | — |
Top 12 Life Sciences companies in Waltham
#1
Public · Waltham, Massachusetts · founded 2009 · 34 employees$115.5Mraised▾
Public · Waltham, Massachusetts · founded 2009 · 34 employees
Developer of ophthalmic treatments based on its mucosal penetrating product platform. It offers therapies for severe ophthalmic diseases. The company’s MPP drug delivery technology platform allows therapeutic agents to pass through the mucus layer(tears) of the ocular surface, facilitating penetration into deeper tissues of the eye, including the aqueous humor and retina. Its solutions are used in treating severe ophthalmic diseases, including ocular inflammation and wet age-related macular degeneration. Its drug pipeline includes KPI-121, an ophthalmic MPP suspension in development for the treatment of post-surgical inflammation , dry eye , meibomian gland disease. Also developing MPP based topical drugs for AMD (orphan indication). It has applications in the treatment of both anterior and posterior chamber eye diseases.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 22%Product
top 24%Talent
top 33%News
top 34%Moat
top 35%Patents
top 37%Funding: Raised $115M across 14 rounds · 14 rounds over 17 yrs (0.8/yr) · Last round Post IPO (Mar 2026)
Product: 2 distinct product lines · Company stage: Public
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated · 2 leadership moves in 12 mo
Audience (LinkedIn): 23k LinkedIn followers — 5.2% of this cohort's audience
Funding rounds
- Mar 2026Post IPO$1.8M
- Jan 2026Post IPO$2.3M
- Dec 2024Post IPO$10.8M
- Jun 2024Post IPO$12.5M
Founders & team
Investors
Ysios Capital, Third Rock Ventures, Polaris Partners, Crown Venture Investment Fund, Lux Capital, Lighthouse Capital Partners
Tech stack
Amazon CloudfrontAmazon S3Amazon Web ServicesBootstrapGodaddyGoogle Font Api
#2
Public · Waltham, Massachusetts · founded 2024$400Mraised▾
Public · Waltham, Massachusetts · founded 2024
Developer of therapies for treating obesity and related conditions. It offers a pipeline of drug candidates which include KAI-9531 a GLP-1/GIP receptor dual agonist formulated as an injectable peptide, KAI-7535 is an oral small molecule, KAI-9531 is a GLP-1/GIP receptor, and KAI-9531 is a GLP-1/GIP receptor for the treatment of obesity and type 2 diabetes.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 12%Growth
top 20%News
top 22%Moat
top 31%Tech
top 40%Talent
bottom 41%Funding: Raised $400M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series B (Oct 2025)
Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
News: 6 BI events in 12 mo (of 6 tracked, 2 types) · 5 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: IPO, Leadership
Audience (LinkedIn): 17k LinkedIn followers — 4.0% of this cohort's audience
Funding rounds
- Oct 2025Series B$600M
- Oct 2024Series A$400M
Founders & team
Investors
Atlas Venture, Bain Capital Life Sciences, RTW Investments, Bain Capital Private Equity, Adage Capital Management, CPP Investments
Tech stack
AccessibeAcquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform Launch
#3
Acquired · Waltham, Massachusetts · founded 2007 · 10 employees$247Mraised▾
Acquired · Waltham, Massachusetts · founded 2007 · 10 employees
Innovating central nervous system disorder treatments with clinical expertise and patient focus. This biopharmaceutical company is dedicated to developing innovative therapies for central nervous system disorders. Their core expertise lies in clinical development, focusing on designing trials with endpoints directly related to patient benefit. They are committed to recruiting patients who will benefit most from their product candidates. The company's pipeline includes programs targeting schizophrenia and Parkinson's disease. They leverage their skills in clinical development to address unmet needs in these disease areas. They are focused on advancing research and development to improve the lives of individuals affected by these conditions. The company is committed to innovation and scientific rigor in their pursuit of new treatments.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Patents
top 22%Funding
top 26%Innovation
top 27%Fin. health
bottom 48%Moat
bottom 48%Global
bottom 44%Patents: 216 patents matched (strict assignee match) · 111 filings since 2022 vs 89 in 2017-21 · Latest publication 2025
Funding: Raised $247M across 4 rounds · 4 rounds over 11 yrs (0.4/yr) · Last round Post IPO (Oct 2025)
Innovation: 216 patents (top 12% of patent-holders) · 111 filings since 2022 vs 89 in 2017-21
Funding rounds
- Oct 2025Post IPO$200M
- Jun 2023Post IPO—
- Mar 2016Post IPO$1M
- Mar 2015Post IPO$31M
Investors
Oxford Finance, SVB, Boehringer Ingelheim, Federated Hermes, Vivo Capital, Janus Henderson Investors
Tech stack
BootstrapFont AwesomeGoogle AnalyticsHstsJqueryJquery Migrate
#4
Series B · Waltham, Massachusetts · founded 2017 · 15 employees$104Mraised▾
Series B · Waltham, Massachusetts · founded 2017 · 15 employees
Developer of therapeutics for the treatment of multiple diseases. The company develops small-molecule therapies that selectively target and silence actively firing nociceptors to treat conditions like chronic cough, itch, pain, and inflammation.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 23%Talent
top 28%Moat
top 39%Global
bottom 39%Market
bottom 34%News
bottom 18%Funding: Raised $104M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Series B (Dec 2025)
Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 3k LinkedIn followers
Funding rounds
- Dec 2025Series B$23M
- Feb 2024Series B$62M
- Jan 2021Series A$15M
- Apr 2019Series A$27M
Founders & team
Investors
Arkin Holdings, Monograph, Canaan, F-Prime Capital, Mass General Brigham, Mission BioCapital
#5
Series B · Waltham, Massachusetts · founded 2021 · 38 employees$110Mraised▾
Series B · Waltham, Massachusetts · founded 2021 · 38 employees
Developer of precision medicine for the treatment of cancer. The company has a molecular glue discovery platform to regulate disease targets powered by high-resolution structural insights, and computational tools for cancer indications.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 24%Moat
top 28%Talent
top 38%Patents
top 41%News
top 43%Innovation
top 47%Funding: Raised $110M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series B (Nov 2025)
Moat: Editorial + unicorn rating 8/10 · IP moat: 21 patents · Soonicorn
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- Nov 2025Series B$120.1M
- Apr 2022Series A$42.6M
Founders & team
Investors
Lightspeed Venture Partners, Citadel, Logos, Pfizer Venture Investments, Ascenta Capital, Bessemer Venture Partners
Tech stack
AngularCart FunctionalityCore-JsDocusignGoogle Hosted LibrariesGoogle Maps
#6
Series B · Waltham, Massachusetts · founded 2016 · 1 employees$25.2Mraised▾
Series B · Waltham, Massachusetts · founded 2016 · 1 employees
Platform offering intradermal energy solutions for skin treatments. It provides aesthetic treatments aim to address skin pigmentation issues and rejuvenate skin color. It utilize imaging and artificial intelligence to create personalized treatment plans for patients.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 6k LinkedIn followers
Hiring: 1 hiring post in 12 mo (public) · hiring: Production Supervisor
Funding rounds
- Feb 2026Series B$19.6M
- Apr 2024Series B$25.2M
Founders & team
Tech stack
AkismetAmazon Web ServicesApple Icloud MailCdnjsCloudflareCloudflare Bot Management
#7
Series D · Waltham, Massachusetts · founded 2005 · 16 employees$69.9Mraised▾
Series D · Waltham, Massachusetts · founded 2005 · 16 employees
Arsenal Medical is developing polymer-based foams and fibers. The company is developing a system that injects an in-situ curing elastomeric polymer material that fills and seals the aneurysm sac around a stent-graft.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 20%Talent
top 23%Product
top 26%Moat
top 26%Patents
top 27%Innovation
top 35%Funding: Raised $69.9M across 21 rounds · 21 rounds over 21 yrs (1.0/yr) · Last round Grant (prize money) (Jul 2025)
Talent: 5 named leaders on record · 5 C-suite/founder profiles curated
Product: 3 distinct product lines · Company stage: Series D
Audience (LinkedIn): 2k LinkedIn followers
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Jul 2025Grant (prize money)$314.4K
- May 2021Grant (prize money)$1.9M
- Jul 2020Grant (prize money)$367.2K
- Jun 2019Series D$6M
Founders & team
Investors
Intersouth Partners, Polaris Partners, North Bridge Venture Partners, HHS, National Oceanic and Atmospheric Administration, Springboard Enterprises
Tech stack
CloudflareCloudflare Bot ManagementGoogle AnalyticsGoogle Font ApiIsotopeJplayer
#8
Public · Waltham, Massachusetts · founded 2016 · 72 employees$233Mraised▾
Public · Waltham, Massachusetts · founded 2016 · 72 employees
Developer of immunotherapies for the treatment of cancer. The company is developing its proprietary technology to create an IO therapy that is activated selectively within the tumor. The product XTX201 (IL-2) induces immune activity in tumors without the toxicity seen with non-selective IL-2s, XTX101, XTX301, and XTX401 demonstrates antitumor activity.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Funding
top 25%Growth
top 27%Moat
top 28%Fin. health
top 41%Market
top 43%Tech
top 45%Funding: Raised $233M across 5 rounds · 5 rounds over 10 yrs (0.5/yr) · Last round Post IPO (Feb 2025)
Growth: Headcount 30 → 72 (+140%) across vintages · Revenue +590% YoY · Web rank 10,000,000 → 50,000,000 YoY
Moat: Top 15% by revenue among 13 tracked Immunotherapy companies · Editorial + unicorn rating 6/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 11k LinkedIn followers — 2.6% of this cohort's audience
Funding rounds
- Feb 2025Post IPO$10M
- Jan 2021Series C$95M
- Mar 2020Series B$100.5M
- Sep 2018Series A$30M
Founders & team
Investors
Takeda Ventures, SV Health Investors, MRLV, RiverVest Venture Partners, F-Prime Capital, Bay City Capital
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#9
Series D · Waltham, Massachusetts · founded 2016 · 12 employees$110.3Mraised▾
Series D · Waltham, Massachusetts · founded 2016 · 12 employees
Developer of small molecule therapeutics for central nervous system disorder. The company's flagship candidate AB-2004 is for the gut-brain axis treatment paradigm for neurodegenerative diseases like autism and Parkinson's disease. It is an oral-based product and stays in the GI tract and removes certain metabolites for the treatment of neurology diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers
Activity: 1 partnerships (incl. Vertero) announced in 12 mo
Funding rounds
- Jan 2025Series D$19.4M
- Oct 2023Series C$11.1M
- Oct 2021Series C$37.2M
- Jul 2020Grant (prize money)$440K
Founders & team
Investors
One Ventures, UTokyo Innovation Platform, Longwood Fund, Seventure Partners, Taiho Ventures, Autism Impact Fund
#10
Series B · Waltham, Massachusetts · founded 2023$207Mraised▾
Series B · Waltham, Massachusetts · founded 2023
Developer of functional antibodies for the treatment of immunological and inflammatory disorders. The company is pioneering a mendelian genetics-informed precision medicine which includes TRIV-509 that targets kallikreins 5 and 7 (KLK5/7), promising targets for the treatment of atopic dermatitis, asthma, and other inflammatory indications.
Funding rounds
- Oct 2024Series B$115M
- Oct 2023Series A$92M
Founders & team
Investors
Atlas Venture, Cormorant Asset Management, Orbimed, Viking Global Investors, Invus, Polaris Partners
#11
Acquired · Waltham, Massachusetts · founded 2012 · 36 employees$79.9Mraised▾
Acquired · Waltham, Massachusetts · founded 2012 · 36 employees
SpectraWAVE offers diagnostic photonic imaging. The company offers diagnosis and treatment of cardiovascular disease through the development of optical diagnostic and therapeutic devices.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 11k LinkedIn followers — 2.5% of this cohort's audience
Activity: 1 product launches · 1 partnerships (incl. Valley Health System) announced in 12 mo
Funding rounds
- Sep 2024Series B$50.3M
- Feb 2021Series A$13.2M
- May 2019Series A$16.4M
Founders & team
Investors
Deerfield, Johnson & Johnson Innovation – JJDC, S3 Ventures, Lumira Ventures, SV Health Investors, Deerfield Mg
Tech stack
Animate.CssBackbone.JsBeaver BuilderCloudflareCloudflare Bot ManagementFont Awesome
#12
Series D · Waltham, Massachusetts · founded 2014 · 126 employees$231.4Mraised▾
Series D · Waltham, Massachusetts · founded 2014 · 126 employees
Provider of precision medicine based on liquid biopsy test. The company's platform identifies which drug will work based on the patient's fundamental blood test report. It offers PrismRA is a blood-based test that predicts patients respond to anti-TNF therapy before the drug is prescribed. The company focuses on autoimmune, neurological, and cardiovascular diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 30k LinkedIn followers — 6.9% of this cohort's audience
Activity: 2 product launches · 2 partnerships (incl. Maxymune Therapeutics) announced in 12 mo
Funding rounds
- May 2024Series D$5.8M
- Feb 2022Series D$110M
- Mar 2021Series C$82M
- Feb 2020Series B—
Founders & team
Investors
Optum Ventures, aMoon, Northpond Ventures, Echo Health Ventures, Khosla Ventures, Alumni Ventures
Tech stack
WordpressMysqlPhpNginxJquery MigrateJquery
Funding & investor landscape
$7.2Btotal disclosed funding
88companies funded
329disclosed rounds
0rounds last 90 days
Most active investors
Atlas Venture6 rounds
Notable founders
Justin Hanes
Co-Founder · Kala Pharmaceuticals
Colin Gardner
EX-Co-Founder · Kala Pharmaceuticals
Ron Renaud
Founder & CEO · Kailera
Clifford Woolf
Co-Founder · Nocion Therapeutics
Bruce Bean
Co-Founder · Nocion Therapeutics
Jesse Chen
Co-Founder & Chief Technology Officer · TRIANA Biomedicines
Patrick Trojer
Chief Executive Officer & President · TRIANA Biomedicines
Irina Erenburg
CEO · AVAVA
Eric Stern
Co-Founder & CTO · Arsenal Medical
George Whitesides
Co-Founder · Arsenal Medical
Rene Russo
CEO · Xilio Therapeutics
A Campbell
CEO · Axial Therapeutics
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and steady — the enthusiastic (strongly-positive) share moved 44% → 42% across 2008–2026.
top research entities
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
leading researchers
Stylianos Chatzimanolis · TARIK DEDOVIC · KATH-RYN ANN F. HANKINS · Christoforos Pavlou · Giannis Bolanakis · Ashley R Tetens · Tyler Findlay · Jordyn Craig-Schwartz
▲
Breakthroughs2,038 · 33%
▼ 41%→30% share
▼0.7× share momentum0 median citations71% since 2021mostly empirical
Gene-focused breakthrough research surged from 33 to 164 papers, driving transcription and antibody discovery simultaneously.
rising sub-themes (early→recent)
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
Newly emergingIdentification (biology) 0→18 · Function (biology) 0→18 · Reporter gene 0→16
Landmark U1 snRNP regulates cancer cell migration and invasion in vitro · 7,224 cites
◆
Advancements2,118 · 34%
▲ 29%→35% share
▲1.2× share momentum0 median citations80% since 2021mostly empirical
Cell culture and gene expression advancements each jumped from 3 to 62 papers, signaling intensifying bioprocess development.
rising sub-themes (early→recent)
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
Newly emergingIdentification (biology) 0→27 · Probiotic 0→24 · Cultivar 0→23
Landmark Using Deep Learning for Image-Based Plant Disease Detection · 4,262 cites
▼
Concerns1,006 · 16%
▼ 17%→15% share
▼0.9× share momentum0 median citations73% since 2021mostly empirical
Antibiotic resistance concern papers tripled from 15 to 45, compounding newly emerging animal health and pest management signals.
rising sub-themes (early→recent)
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Newly emergingQuality (philosophy) 0→27 · Animal health 0→14 · Integrated pest management 0→13
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · United States
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston351 · +0.52
New York319 · +0.47
SF Bay Area235 · +0.57
Philadelphia115 · +0.60
San Diego101 · +0.59
Seattle95 · +0.46
Chicago95 · +0.57
Los Angeles93 · +0.61
Pittsburgh65 · +0.54
Ann Arbor65 · +0.58
PATENT SIGNAL · United States
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
457,918 filings8,000 assigneespeak 51616/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
How many Life Sciences companies are there in Waltham, United States?
Radar tracks 126 indexable Life Sciences companies headquartered in Waltham, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Waltham, United States?
The Life Sciences companies in Waltham, United States on this list have raised a combined $7.2B in disclosed equity funding across 88 funded companies.
Which is the highest-funded Life Sciences company in Waltham, United States?
Adagio is the highest-funded Life Sciences company in Waltham, United States, with $466M in disclosed equity funding.
How many Life Sciences companies in Waltham, United States are funded?
88 of the 126 Life Sciences companies in Waltham, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Waltham, United States?
1 Life Sciences company in Waltham, United States on this list is valued at $1B or more.
Who are the top investors in Waltham, United States Life Sciences companies?
The most active investors in Waltham, United States Life Sciences companies on this list include HHS, Venrock, Polaris Partners, Orbimed, SV Health Investors.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.